Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab for Eosinophilia in Loa Loa Infection
NCT01111305Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2010
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in loiasis comparing Reslizumab + DEC with Placebo + DEC (2 arms). Primary endpoint: Peak Eosinophil Count Post-treatment at 7 days. Started Apr 2010; status: completed.
02
Drugs
reslizumab
03
Conditions
loiasis
Beyond the preview
Go deeper on NCT01111305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111305.